STING agonists promote DC maturation, improve antigen presentation, and synergize with anti-PD-1 therapy to strengthen tumor-infiltrating CD8+ T cell expansion, showing efficacy in several preclinical models [15, 70, 159]. The gene discussed is CD8A; the disease is neoplasm.